{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:12:54Z","timestamp":1787170374859,"version":"build-2736575974"},"reference-count":31,"publisher":"American Diabetes Association","issue":"5","content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2003,5,1]]},"abstract":"<jats:p>OBJECTIVE\u2014To evaluate the performance of the in-office dermatophyte test medium (DTM) culture when used to confirm the diagnosis of onychomycosis in diabetic patients.<\/jats:p>\n               <jats:p>RESEARCH DESIGN AND METHODS\u2014Nail samples from 184 diabetic patients who exhibited symptoms consistent with toenail onychomycosis were screened for dermatophyte fungal infection using DTM, potassium hydroxide evaluation, and central mycology laboratory culture tests. The diabetic patient group investigated in this study is a subset of a heterogeneous set of patients who participated in a nationwide survey designed to investigate the use of fungal culture tests by dermatologists, podiatrists, and primary care physicians described in detail elsewhere. The overall sensitivity of the DTM and central laboratory culture methods was estimated and compared. Sensitivity differences between DTM and central laboratory culture methods were tested for statistical significance using the McNemar statistic.<\/jats:p>\n               <jats:p>RESULTS\u2014DTM culture was positive in 102 of 184 patients (55%), while the central laboratory culture test detected the existence of fungal infection in 78 of 184 (42%). The two tests were in agreement (both positive or both negative) in 114 of 184 patients (62%). Central laboratory culture identified dermatophytes as the pathogen in 91% of positive cases.<\/jats:p>\n               <jats:p>CONCLUSIONS\u2014DTM is a convenient and inexpensive culture test that can be used to confirm dermatophyte infections in diabetic patients with presumed onychomycosis. We found this test to be well suited for use in the primary care setting. Because oral antifungal agents are effective against dermatophyte species, which cause the vast majority of nail infections, diagnosis of onychomycosis requires confirmation of dermatophyte infection only, not identification of genus and species. DTM fulfills this requirement and has a diagnostic yield comparable to central laboratory culture.<\/jats:p>","DOI":"10.2337\/diacare.26.5.1480","type":"journal-article","created":{"date-parts":[[2007,3,5]],"date-time":"2007-03-05T22:51:27Z","timestamp":1173135087000},"page":"1480-1484","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":12,"title":["Dermatophyte Test Medium Culture for Evaluating Toenail Infections in Patients With Diabetes"],"prefix":"10.2337","volume":"26","author":[{"given":"Phoebe","family":"Rich","sequence":"first","affiliation":[{"name":"Department of Dermatology, Oregon Health Sciences University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence B.","family":"Harkless","sequence":"additional","affiliation":[{"name":"Department of Orthopedics, University of Texas Health Science Center, San Antonio, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercem S.","family":"Atillasoy","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Thomas Jefferson University, Philadelphia, Pennsylvania"},{"name":"Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","reference":[{"key":"2022031216472234400_R1","doi-asserted-by":"crossref","unstructured":"Gupta AK, Konnikov N, MacDonald P, Rich P, Rodger NW, Edmonds MW, McManus R, Summerbell RC: Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre survey. Br J Dermatol\u2008139:665\u2013671, 1998","DOI":"10.1046\/j.1365-2133.1998.02464.x"},{"key":"2022031216472234400_R2","doi-asserted-by":"crossref","unstructured":"Ghannoum MA, Hajjeh RA, Scher R, Konnikov N, Gupta AK, Summerbell R, Sullivan S, Daniel R, Krusinski P, Fleckman P, Rich P, Odom R, Aly R, Pariser D, Zaiac M, Rebell G, Lesher J, Gerlach B, Ponce-De-Leon GF, Ghannoum A, Warner J, Isham N, Elewski B: A large-scale North American study of fungal isolates from nails: the frequency of onychomycosis, fungal distribution, and antifungal susceptibility patterns. J Am Acad Dermatol\u200843:641\u2013648, 2000","DOI":"10.1067\/mjd.2000.107754"},{"key":"2022031216472234400_R3","unstructured":"Boyko WL, Doyle JJ, Ryu S, Gause D: Onychomycosis and its impact on secondary infection development in the diabetic population (Poster). Presented at the 4th annual meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Arlington, VA, 23\u201326 May 1999"},{"key":"2022031216472234400_R4","doi-asserted-by":"crossref","unstructured":"Greene RA, Scher RK: Nail changes associated with diabetes mellitus. J Am Acad Dermatol\u200816:1015\u20131021, 1987","DOI":"10.1016\/S0190-9622(87)70131-5"},{"key":"2022031216472234400_R5","doi-asserted-by":"crossref","unstructured":"Levy LA: Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc\u200887:546\u2013550, 1997","DOI":"10.7547\/87507315-87-12-546"},{"key":"2022031216472234400_R6","doi-asserted-by":"crossref","unstructured":"Rich P: Special patient populations: onychomycosis in the diabetic patient. J Am Acad Dermatol\u200835:S10\u2013S12, 1996","DOI":"10.1016\/S0190-9622(96)90063-8"},{"key":"2022031216472234400_R7","doi-asserted-by":"crossref","unstructured":"Rich P, Hare A: Onychomycosis in a special patient population: focus on the diabetic. Int J Dermatol\u200838(Suppl. 2):17\u201319, 1999","DOI":"10.1046\/j.1365-4362.1999.00009.x"},{"key":"2022031216472234400_R8","doi-asserted-by":"crossref","unstructured":"Drake LA, Scher RK, Smith EB, Faich GA, Smith SL, Hong JJ, Stiller MJ: Effect of onychomycosis on quality of life. J Am Acad Dermatol\u200838:702\u2013704, 1998","DOI":"10.1016\/S0190-9622(98)70199-9"},{"key":"2022031216472234400_R9","doi-asserted-by":"crossref","unstructured":"Lubeck DP: Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol\u200838:S64\u2013S68, 1998","DOI":"10.1016\/S0190-9622(98)70487-6"},{"key":"2022031216472234400_R10","doi-asserted-by":"crossref","unstructured":"Schein JR, Gause D, Stier DM, Lubeck DP, Bates MM, Fisk R: Onychomycosis: baseline results of an observational study. J Am Podiatr Med Assoc\u200887:512\u2013519, 1997","DOI":"10.7547\/87507315-87-11-512"},{"key":"2022031216472234400_R11","doi-asserted-by":"crossref","unstructured":"Evans EG: Causative pathogens in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol\u200838:S32\u2013S36, 1998","DOI":"10.1016\/S0190-9622(98)70481-5"},{"key":"2022031216472234400_R12","doi-asserted-by":"crossref","unstructured":"Kemna ME, Elewski BE: A U.S. epidemiologic survey of superficial fungal diseases. J Am Acad Dermatol\u200835:539\u2013542, 1996","DOI":"10.1016\/S0190-9622(96)90675-1"},{"key":"2022031216472234400_R13","doi-asserted-by":"crossref","unstructured":"Summerbell RC: Epidemiology and ecology of onychomycosis. Dermatology\u2008194(Suppl. 1):32\u201336, 1997","DOI":"10.1159\/000246182"},{"key":"2022031216472234400_R14","doi-asserted-by":"crossref","unstructured":"Elewski BE: Onychomycosis: pathogenesis, diagnosis, and management. Clin Microbiol Rev\u200811:415\u2013429, 1998","DOI":"10.1128\/CMR.11.3.415"},{"key":"2022031216472234400_R15","doi-asserted-by":"crossref","unstructured":"Gupta AK, Shear NH: The new oral antifungal agents for onychomycosis of the toenails. J Eur Acad Derm Venereol\u200813:1\u201313, 1999","DOI":"10.1111\/j.1468-3083.1999.tb00837.x"},{"key":"2022031216472234400_R16","doi-asserted-by":"crossref","unstructured":"Niewerth M, Korting HC: Management of onychomycoses. Drugs\u200858:283\u2013296, 1999","DOI":"10.2165\/00003495-199958020-00005"},{"key":"2022031216472234400_R17","doi-asserted-by":"crossref","unstructured":"Elewski BE: Diagnostic techniques for confirming onychomycosis. J Am Acad Dermatol\u200835:S6\u2013S9, 1996","DOI":"10.1016\/S0190-9622(96)90062-6"},{"key":"2022031216472234400_R18","doi-asserted-by":"crossref","unstructured":"Pierard GE, Arrese JE, De Doncker P, Pierard-Franchimont C: Present and potential diagnostic techniques in onychomycosis. J Am Acad Dermatol\u200834:273\u2013277, 1996","DOI":"10.1016\/S0190-9622(96)80122-8"},{"key":"2022031216472234400_R19","doi-asserted-by":"crossref","unstructured":"Taplin D, Zaias N, Rebell G, Blank H: Isolation and recognition of dermatophytes on a new medium (DTM). Arch Dermatol\u200899:203\u2013209, 1969","DOI":"10.1001\/archderm.99.2.203"},{"key":"2022031216472234400_R20","unstructured":"Gupta AK, Humke S: The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol\u200810:379\u2013384, 2000"},{"key":"2022031216472234400_R21","doi-asserted-by":"crossref","unstructured":"Feinstein AR: Clinimetrics. New Haven, CT, Yale University Press, 1987","DOI":"10.2307\/j.ctt1xp3vbc"},{"key":"2022031216472234400_R22","unstructured":"Stokes ME, Davis CE, Koch GG: Categorical Data Analysis Using the SAS Software. 2nd ed. Cary, NC, SAS Institute, 2000"},{"key":"2022031216472234400_R23","doi-asserted-by":"crossref","unstructured":"Daniel CR III, Elewski B: The diagnosis of nail fungus infection, revisited. Arch Dermatol\u2008136:1162\u20131164, 2000","DOI":"10.1001\/archderm.136.9.1162"},{"key":"2022031216472234400_R24","doi-asserted-by":"crossref","unstructured":"Elewski BE, Leyden J, Rinaldi M, Atillasoy E: Office-based confirmation of onychomyosis: a U.S. prospective survey. Arch Intern Med\u2008162:2133\u20132138, 2002","DOI":"10.1001\/archinte.162.18.2133"},{"key":"2022031216472234400_R25","unstructured":"Albreski DA, Gupta AK, Gross EG: Onychomycosis in diabetes: management considerations (Review). Postgrad Med (Spec. no.):26\u201330, 1999"},{"key":"2022031216472234400_R26","doi-asserted-by":"crossref","unstructured":"Elewski BE: Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafine (Letter). Arch Dermatol\u2008133:1317\u20131318, 1997","DOI":"10.1001\/archderm.133.10.1317"},{"key":"2022031216472234400_R27","doi-asserted-by":"crossref","unstructured":"Gupta AK, Jain HC, Lynde CW, MacDonald P, Cooper EA, Summerbell RC: Prevalence and epidemiology of onychomycosis in patients visiting physicians\u2019 offices: a multicenter Canadian survey of 15,000 patients. J Am Acad Dermatol\u200843:244\u2013248, 2000","DOI":"10.1067\/mjd.2000.104794"},{"key":"2022031216472234400_R28","doi-asserted-by":"crossref","unstructured":"Harvey CK, Richardson A: Techniques for obtaining specimens for culture to confirm onychomycosis. J Am Podiatr Assoc\u200890:394\u2013396, 2000","DOI":"10.7547\/87507315-90-8-394"},{"key":"2022031216472234400_R29","doi-asserted-by":"crossref","unstructured":"Farkas B, Paul C, Dobozy A, Hunyadi J, Horvath A, Fekete G: Terbinafine (Lamisil) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol\u2008146:254\u2013260, 2002","DOI":"10.1046\/j.1365-2133.2002.04606.x"},{"key":"2022031216472234400_R30","doi-asserted-by":"crossref","unstructured":"Hall M, Monka C, Krupp P, O\u2019Sullivan D: Safety of oral terbinafine: results of a postmarketing surveillance study in 25,884 patients. Arch Dermatol\u2008133:1213\u20131219, 1997","DOI":"10.1001\/archderm.133.10.1213"},{"key":"2022031216472234400_R31","doi-asserted-by":"crossref","unstructured":"Verspeelt J, Marynissen G, Gupta AK, De Doncker P: Safety of itraconazole in diabetic patients. Dermatology\u2008198:382\u2013384, 1999","DOI":"10.1159\/000018152"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/5\/1480\/591713\/dc0503001480.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/26\/5\/1480\/591713\/dc0503001480.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T17:22:29Z","timestamp":1647105749000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/26\/5\/1480\/24461\/Dermatophyte-Test-Medium-Culture-for-Evaluating"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":31,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5,1]]}},"URL":"https:\/\/doi.org\/10.2337\/diacare.26.5.1480","relation":{},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}